#WeWontRest in the fight against COVID-19
As the impact of COVID-19 continues to be felt across the world, the biopharmaceutical industry in Europe remains committed to global efforts to care for those affected, contain the outbreak and develop resources to tackle future outbreaks.
While governments contend with implementing appropriate public health measures and health systems are treating or preparing to treat unprecedented numbers of patients requiring intensive care, our industry is focused on three key areas:
We are committed to working collaboratively across the research and healthcare communities, utilising our world-leading science, people and resources to tackle this outbreak. As part of the global fight against COVID-19, we published a series of commitments on tackling this pandemic.